Advertisement
U.S. markets close in 5 minutes
  • S&P 500

    5,259.43
    +10.94 (+0.21%)
     
  • Dow 30

    39,829.30
    +69.22 (+0.17%)
     
  • Nasdaq

    16,396.38
    -3.15 (-0.02%)
     
  • Russell 2000

    2,121.54
    +7.19 (+0.34%)
     
  • Crude Oil

    83.00
    +1.65 (+2.03%)
     
  • Gold

    2,240.20
    +27.50 (+1.24%)
     
  • Silver

    24.98
    +0.23 (+0.92%)
     
  • EUR/USD

    1.0791
    -0.0039 (-0.36%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2622
    -0.0016 (-0.13%)
     
  • USD/JPY

    151.3750
    +0.1290 (+0.09%)
     
  • Bitcoin USD

    70,770.09
    +2,115.81 (+3.08%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

StemCells receives FDA authorization of IND for spinal cord injury

StemCells announced that the FDA has authorized the company's Investigational New Drug, or IND, application for clinical testing of the company's proprietary HuCNS-SC human neural stem cells as a treatment for spinal cord injury. As a first action under this IND, the company is working to open U.S. sites for its Phase I/II clinical trial for chronic spinal cord injury, which is currently underway in Switzerland and Canada.

Advertisement